Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Coronavirus Hits Elective Procedures: 3 MedTech Stocks To Avoid

By Zacks Investment ResearchStock MarketsMar 26, 2020 07:49AM ET
Coronavirus Hits Elective Procedures: 3 MedTech Stocks To Avoid
By Zacks Investment Research   |  Mar 26, 2020 07:49AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Since the first detection in central China in December, coronavirus has turned into a full-blown pandemic, and its panoptic impact has left the world rattled and shocked. As of Mar 26, the number of people infected globally has exceeded 460,000, while the number of deaths recorded is at least 21,200. In the United States alone, there are at least 65,201 cases with the death toll at 928, so far.

According to another CNBC report, analysts from the Economic Intelligence Unit (“EIU”) anticipates the virus to infect about 50% of the world population, with 20% cases being severe and 1-3% resulting in deaths. Consequently, EIU projected global growth to stand at 1% in 2020 (down from the expectation of 2.3% before the coronavirus outbreak). Analysts also added that it would mark the lowest rate in global gross domestic product (GDP) growth since the global financial crisisin 2008.

Crippling Economic Impact

The U.S. economic outlook looks dreary with millions now facing unemployment and businesses witnessing a steep decline. The coronavirus (also termed as COVID-19) fallout has been so severe that many economists are of the opinion that the United States is heading into a recession.

Per a report by The New York Times, Greg Daco, chief U.S. economist at Oxford Economic, is certain that the economy is heading for a deep recession with at least two consecutive quarters of economic decline (with output projected to fall 0.4% in the first quarter and 12% in the second). This would reflect the biggest quarterly contraction on record. Goldman Sachs (NYSE:GS), estimates this contraction to be as much as 24% in the second quarter.

Elective Procedures in MedTech Reeling Under the Coronavirus Impact

Going by a MedTech Dive report, Moody’s Investors Service has lowered its outlook for the medical device sector from positive to stable, citing a global economic slowdown and shift in healthcare resources toward combating the novel coronavirus.

Elective procedures have been lucrative for MedTech companies but the outbreak has put the same under significant threat. CMS has urged hospitals to postpone non-essential elective surgeries, such as hip and knee replacements, and focus on preparing for COVID-19 patients. The United States could witness 3-4% of procedures impacted across orthopedics and interventional cardiology. This disruption is expected to dent MedTech sales in the near term.

Robotic Surgery giant, Intuitive Surgical (NASDAQ:ISRG) , has already witnessed disruptions to procedures and delays in case of new system placements due to the coronavirus outbreak. The company anticipates the procedure volume and system replacement disruption to intensify with the coronavirus outbreak showing no signs of letting up.

Stocks Grappling With Coronavirus Crisis

Needless to say, that the panic triggered by the escalating coronavirus pandemic has been weighing heavily on investors sentiments by sending markets into frenzy. Here we will look at three MedTech stocks that have been struggling to combat this coronavirus-induced crisis.

Becton, Dickinson and Company (NYSE:BDX) , also known as BD, has mentioned in its first-quarter fiscal 2020 earnings call that it expects to witness a headwind of $20-$30 million in fiscal 2020. From a supply chain perspective, the Zacks Rank #4 (Sell) company currently has sufficient inventory of the products that it exports from China to meet current demand levels. However, considering the rapid spread of the virus, we remain skeptical regarding the company’s operational capability following the end of current inventory.

Over the past two months, the company’s shares have lost 12.6%, compared with the industry’s decline of 7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Abiomed, Inc.’s (NASDAQ:ABMD) flagship product line, Impella (world’s smallest heart pump), is a support system of percutaneous, catheter-based devices offering hemodynamic support to the heart. With interventional cardiology procedures expected to take a hit, the product line is likely to be under pressure in the near term.

This Zacks Rank #4 stock has lost 11.9% over the past two months, compared with the industry’s decline of 5.9%.

Orthofix Medical Inc. (NASDAQ:OFIX) develops, produces and markets medical devices. The company offers spine fixation, biological and other orthopedic and spine solutions. As discussed above, orthopedic procedures are anticipated to bear an impact due to this outbreak and as a result the company’s product line might take a hit.

This Zacks Rank #5 (Strong Sell) stock has lost 23.5% over the past two months, compared with the industry’s decline of 6%.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report

ORTHOFIX MEDICAL INC. (OFIX): Free Stock Analysis Report

ABIOMED, Inc. (ABMD): Free Stock Analysis Report

Original post

Zacks Investment Research
Coronavirus Hits Elective Procedures: 3 MedTech Stocks To Avoid

Related Articles

Declan Fallon
Indices Attempt Support Rally By Declan Fallon - Sep 17, 2021 2

Markets aren't exactly powering higher but there is an attempt to develop some form of swing low. The NASDAQ has the clearest opportunity. The last couple of 'white' candlesticks...

Coronavirus Hits Elective Procedures: 3 MedTech Stocks To Avoid

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
m mori
m mori Nov 18, 2020 2:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
you BETTER check out medical company that's going to r o o l over a lot of these company's. J and J. for starters see the next multiple billion $ company GNBT bye by
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email